Disease: Tumor Progression ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Experimental disruption of ALCAM-mediated adhesions implies that this IgSF member contributes to tumor progression through dynamic turnover of the protein at the cell surface. 30778704 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Screening of potential mRNAs targeted by miR-194/192 revealed that expression of genes involved in glucose metabolism (glycogenin 1 (<i>Gyg1</i>)), cell adhesion and migration (activated leukocyte cell adhesion molecule (<i>Alcam</i>)), tumorigenesis and tumor progression (<i>Rap2b</i> and epiregulin (<i>Ereg</i>)), protein SUMOylation (<i>Sumo2</i>), epigenetic regulation (<i>Setd5</i> and Cullin 4B (<i>Cln4b</i>)), and the epithelial-mesenchymal transition (moesin (<i>Msn</i>)) was up-regulated in <i>Hnf4a</i><sup>ΔH</sup> mice. 28465351 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Although ALCAM expression on tumor cells has been linked to tumor invasion and metastatic spread, the contribution of ALCAM expressed in cells forming the tumor stroma to cancer progression has not been investigated. 28822802 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a transmembrane glycoprotein that is involved in tumor progression and metastasis. 27573419 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE In conclusion, an overexpression of CD166 was detected in the benign and malignant salivary gland tumors and its expression in the malignant tumor was associated with the aggressive behavior and tumor progression. 25472586 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Depending on the tumor cell type, ALCAM expression has been reported to be both positively and negatively correlated with cancer progression and metastasis in the literature. 22745734 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 AlteredExpression phenotype BEFREE Our study suggests that overexpression of ALCAM contributes to tumor progression in MM and that ALCAM might be a potential therapeutic target of MM. 22722789 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE CD166/ALCAM has gained increasing attention because of its significant association with tumor progression and the metastatic spread of breast cancer. 21293922 2011
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Loss, rather than overexpression, of membranous CD44s, CD166, and EpCAM is linked to tumour progression. 20606680 2010
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a 105-kDa transmembrane glycoprotein linked with cell migration and development and with cancer progression (malignant melanoma, prostate cancer and, very recently, breast cancer). 16865058 2006
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.100 Biomarker phenotype BEFREE Data on the tissue distribution of ALCAM suggest that this protein is involved in tumor progression and metastasis. 16810131 2006